Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors

Sohee Son, Seungyong Song, So Jin Lee, Solki Min, Sun Ah Kim, Ji Young Yhee, Myung Sook Huh, Ick Chan Kwon, Seo Young Jeong, Youngro Byun, Sun Hwa Kim, Kwang Meyung Kim

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The safe and effective systemic delivery of siRNA is a prerequisite for the successful development of siRNA-based cancer therapeutics. For the enhanced delivery of siRNA, cationic lipids and polymers have been widely used as siRNA carriers to form electrolyte complexes with anionic siRNA. However, the considerable toxicity of strong cationic-charged molecules hampers their clinical use. In this study, we utilized human serum albumin (HSA), which is the most abundant of the plasma proteins, as a siRNA carrier for systemic tumor-targeted siRNA delivery. Both HSA and siRNA molecules were thiol-introduced to improve the binding affinity for each other. The resulting thiolated HSA (tHSA) and polymerized siRNA (psi) formed stable nanosized complexes (psi-tHSAs) by chemical crosslinking and self-crosslinking. After internalization, the psi-tHSAs showed target gene silencing activity invitro comparable to conventional Lipofectamine™-siRNA complexes, without remarkable cytotoxicity. After intravenous injection in tumor-bearing mice, psi-tHSAs accumulated specifically at the tumor sites, leading to efficient gene silencing in the tumors in a sequential manner. The therapeutic VEGF siRNA was loaded into psi-tHSAs, which significantly inhibited tumor-related angiogenesis in PC-3 tumor xenografts and resulted in retarding the growth of PC-3 tumors. The results showed that self-crosslinked psi-tHSA nanocarriers might provide a promising approach for the systemic siRNA therapy of various human cancers.

Original languageEnglish
Pages (from-to)9475-9485
Number of pages11
JournalBiomaterials
Volume34
Issue number37
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Serum Albumin
Small Interfering RNA
Tumors
Neoplasms
Crosslinking
Bearings (structural)
Genes
Molecules
Cytotoxicity
Lipids
Gene Silencing
Toxicity
Electrolytes
Proteins
Plasmas
Polymers
Sulfhydryl Compounds
Heterografts
Intravenous Injections
Vascular Endothelial Growth Factor A

Keywords

  • Cancer therapy
  • Human serum albumin
  • Polymerized siRNA
  • Protein based carrier
  • RNAi

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. / Son, Sohee; Song, Seungyong; Lee, So Jin; Min, Solki; Kim, Sun Ah; Yhee, Ji Young; Huh, Myung Sook; Kwon, Ick Chan; Jeong, Seo Young; Byun, Youngro; Kim, Sun Hwa; Kim, Kwang Meyung.

In: Biomaterials, Vol. 34, No. 37, 01.12.2013, p. 9475-9485.

Research output: Contribution to journalArticle

Son, S, Song, S, Lee, SJ, Min, S, Kim, SA, Yhee, JY, Huh, MS, Kwon, IC, Jeong, SY, Byun, Y, Kim, SH & Kim, KM 2013, 'Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors', Biomaterials, vol. 34, no. 37, pp. 9475-9485. https://doi.org/10.1016/j.biomaterials.2013.08.085
Son, Sohee ; Song, Seungyong ; Lee, So Jin ; Min, Solki ; Kim, Sun Ah ; Yhee, Ji Young ; Huh, Myung Sook ; Kwon, Ick Chan ; Jeong, Seo Young ; Byun, Youngro ; Kim, Sun Hwa ; Kim, Kwang Meyung. / Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. In: Biomaterials. 2013 ; Vol. 34, No. 37. pp. 9475-9485.
@article{1dae6548d4ab49acb86ab9bb50412875,
title = "Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors",
abstract = "The safe and effective systemic delivery of siRNA is a prerequisite for the successful development of siRNA-based cancer therapeutics. For the enhanced delivery of siRNA, cationic lipids and polymers have been widely used as siRNA carriers to form electrolyte complexes with anionic siRNA. However, the considerable toxicity of strong cationic-charged molecules hampers their clinical use. In this study, we utilized human serum albumin (HSA), which is the most abundant of the plasma proteins, as a siRNA carrier for systemic tumor-targeted siRNA delivery. Both HSA and siRNA molecules were thiol-introduced to improve the binding affinity for each other. The resulting thiolated HSA (tHSA) and polymerized siRNA (psi) formed stable nanosized complexes (psi-tHSAs) by chemical crosslinking and self-crosslinking. After internalization, the psi-tHSAs showed target gene silencing activity invitro comparable to conventional Lipofectamine™-siRNA complexes, without remarkable cytotoxicity. After intravenous injection in tumor-bearing mice, psi-tHSAs accumulated specifically at the tumor sites, leading to efficient gene silencing in the tumors in a sequential manner. The therapeutic VEGF siRNA was loaded into psi-tHSAs, which significantly inhibited tumor-related angiogenesis in PC-3 tumor xenografts and resulted in retarding the growth of PC-3 tumors. The results showed that self-crosslinked psi-tHSA nanocarriers might provide a promising approach for the systemic siRNA therapy of various human cancers.",
keywords = "Cancer therapy, Human serum albumin, Polymerized siRNA, Protein based carrier, RNAi",
author = "Sohee Son and Seungyong Song and Lee, {So Jin} and Solki Min and Kim, {Sun Ah} and Yhee, {Ji Young} and Huh, {Myung Sook} and Kwon, {Ick Chan} and Jeong, {Seo Young} and Youngro Byun and Kim, {Sun Hwa} and Kim, {Kwang Meyung}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2013.08.085",
language = "English",
volume = "34",
pages = "9475--9485",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "37",

}

TY - JOUR

T1 - Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors

AU - Son, Sohee

AU - Song, Seungyong

AU - Lee, So Jin

AU - Min, Solki

AU - Kim, Sun Ah

AU - Yhee, Ji Young

AU - Huh, Myung Sook

AU - Kwon, Ick Chan

AU - Jeong, Seo Young

AU - Byun, Youngro

AU - Kim, Sun Hwa

AU - Kim, Kwang Meyung

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The safe and effective systemic delivery of siRNA is a prerequisite for the successful development of siRNA-based cancer therapeutics. For the enhanced delivery of siRNA, cationic lipids and polymers have been widely used as siRNA carriers to form electrolyte complexes with anionic siRNA. However, the considerable toxicity of strong cationic-charged molecules hampers their clinical use. In this study, we utilized human serum albumin (HSA), which is the most abundant of the plasma proteins, as a siRNA carrier for systemic tumor-targeted siRNA delivery. Both HSA and siRNA molecules were thiol-introduced to improve the binding affinity for each other. The resulting thiolated HSA (tHSA) and polymerized siRNA (psi) formed stable nanosized complexes (psi-tHSAs) by chemical crosslinking and self-crosslinking. After internalization, the psi-tHSAs showed target gene silencing activity invitro comparable to conventional Lipofectamine™-siRNA complexes, without remarkable cytotoxicity. After intravenous injection in tumor-bearing mice, psi-tHSAs accumulated specifically at the tumor sites, leading to efficient gene silencing in the tumors in a sequential manner. The therapeutic VEGF siRNA was loaded into psi-tHSAs, which significantly inhibited tumor-related angiogenesis in PC-3 tumor xenografts and resulted in retarding the growth of PC-3 tumors. The results showed that self-crosslinked psi-tHSA nanocarriers might provide a promising approach for the systemic siRNA therapy of various human cancers.

AB - The safe and effective systemic delivery of siRNA is a prerequisite for the successful development of siRNA-based cancer therapeutics. For the enhanced delivery of siRNA, cationic lipids and polymers have been widely used as siRNA carriers to form electrolyte complexes with anionic siRNA. However, the considerable toxicity of strong cationic-charged molecules hampers their clinical use. In this study, we utilized human serum albumin (HSA), which is the most abundant of the plasma proteins, as a siRNA carrier for systemic tumor-targeted siRNA delivery. Both HSA and siRNA molecules were thiol-introduced to improve the binding affinity for each other. The resulting thiolated HSA (tHSA) and polymerized siRNA (psi) formed stable nanosized complexes (psi-tHSAs) by chemical crosslinking and self-crosslinking. After internalization, the psi-tHSAs showed target gene silencing activity invitro comparable to conventional Lipofectamine™-siRNA complexes, without remarkable cytotoxicity. After intravenous injection in tumor-bearing mice, psi-tHSAs accumulated specifically at the tumor sites, leading to efficient gene silencing in the tumors in a sequential manner. The therapeutic VEGF siRNA was loaded into psi-tHSAs, which significantly inhibited tumor-related angiogenesis in PC-3 tumor xenografts and resulted in retarding the growth of PC-3 tumors. The results showed that self-crosslinked psi-tHSA nanocarriers might provide a promising approach for the systemic siRNA therapy of various human cancers.

KW - Cancer therapy

KW - Human serum albumin

KW - Polymerized siRNA

KW - Protein based carrier

KW - RNAi

UR - http://www.scopus.com/inward/record.url?scp=84884814016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884814016&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.08.085

DO - 10.1016/j.biomaterials.2013.08.085

M3 - Article

VL - 34

SP - 9475

EP - 9485

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 37

ER -